Aneurysmal Subarachnoid Hemorrhage — Improving Outcome in Subarachnoid Hemorrhage wIth Nadroparine
Citation(s)
Blasberg R, Johnson D, Fenstermacher J Absorption resistance of cerebrospinal fluid after subarachnoid hemorrhage in the monkey; effects of heparin. Neurosurgery. 1981 Dec;9(6):686-91. doi: 10.1227/00006123-198112000-00012.
Chimowitz MI, Pessin MS Is there a role for heparin in the management of complications of subarachnoid hemorrhage? Stroke. 1987 Nov-Dec;18(6):1169-72. doi: 10.1161/01.str.18.6.1169.
Hayman EG, Patel AP, James RF, Simard JM Heparin and Heparin-Derivatives in Post-Subarachnoid Hemorrhage Brain Injury: A Multimodal Therapy for a Multimodal Disease. Molecules. 2017 May 2;22(5):724. doi: 10.3390/molecules22050724.
Hochart H, Jenkins PV, Smith OP, White B Low-molecular weight and unfractionated heparins induce a downregulation of inflammation: decreased levels of proinflammatory cytokines and nuclear factor-kappaB in LPS-stimulated human monocytes. Br J Haematol. 2006 Apr;133(1):62-7. doi: 10.1111/j.1365-2141.2006.05959.x.
Johnston SC, Selvin S, Gress DR The burden, trends, and demographics of mortality from subarachnoid hemorrhage. Neurology. 1998 May;50(5):1413-8. doi: 10.1212/wnl.50.5.1413.
Mary V, Wahl F, Uzan A, Stutzmann JM Enoxaparin in experimental stroke: neuroprotection and therapeutic window of opportunity. Stroke. 2001 Apr;32(4):993-9. doi: 10.1161/01.str.32.4.993.
Molyneux AJ, Birks J, Clarke A, Sneade M, Kerr RS The durability of endovascular coiling versus neurosurgical clipping of ruptured cerebral aneurysms: 18 year follow-up of the UK cohort of the International Subarachnoid Aneurysm Trial (ISAT). Lancet. 2015 Feb 21;385(9969):691-7. doi: 10.1016/S0140-6736(14)60975-2. Epub 2014 Oct 28. Erratum In: Lancet. 2015 Mar 14;385(9972):946.
RANKIN J Cerebral vascular accidents in patients over the age of 60. II. Prognosis. Scott Med J. 1957 May;2(5):200-15. doi: 10.1177/003693305700200504. No abstract available.
Schweizer TA, Al-Khindi T, Macdonald RL Mini-Mental State Examination versus Montreal Cognitive Assessment: rapid assessment tools for cognitive and functional outcome after aneurysmal subarachnoid hemorrhage. J Neurol Sci. 2012 May 15;316(1-2):137-40. doi: 10.1016/j.jns.2012.01.003. Epub 2012 Jan 26.
Stutzmann JM, Mary V, Wahl F, Grosjean-Piot O, Uzan A, Pratt J Neuroprotective profile of enoxaparin, a low molecular weight heparin, in in vivo models of cerebral ischemia or traumatic brain injury in rats: a review. CNS Drug Rev. 2002 Spring;8(1):1-30. doi: 10.1111/j.1527-3458.2002.tb00213.x.
Tekkok IH, Tekkok S, Ozcan OE, Erbengi T, Erbengi A Preventive effect of intracisternal heparin for proliferative angiopathy after experimental subarachnoid haemorrhage in rats. Acta Neurochir (Wien). 1994;127(1-2):112-7. doi: 10.1007/BF01808557.
Wurm G, Tomancok B, Nussbaumer K, Adelwohrer C, Holl K Reduction of ischemic sequelae following spontaneous subarachnoid hemorrhage: a double-blind, randomized comparison of enoxaparin versus placebo. Clin Neurol Neurosurg. 2004 Mar;106(2):97-103. doi: 10.1016/j.clineuro.2004.01.006.
Yamamoto Y, Smith RR, Bernanke DH Accelerated nonmuscle contraction after subarachnoid hemorrhage: culture and characterization of myofibroblasts from human cerebral arteries in vasospasm. Neurosurgery. 1992 Mar;30(3):337-45. doi: 10.1227/00006123-199203000-00005.
Young E The anti-inflammatory effects of heparin and related compounds. Thromb Res. 2008;122(6):743-52. doi: 10.1016/j.thromres.2006.10.026. Epub 2007 Aug 28.
Zhang ZG, Lu TS, Yuan HY Neuroprotective effects of ultra-low-molecular-weight heparin in vitro and vivo models of ischemic injury. Fundam Clin Pharmacol. 2011 Jun;25(3):300-3. doi: 10.1111/j.1472-8206.2010.00845.x.
Improving Outcome in Subarachnoid Hemorrhage wIth Nadroparine
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
